Estimation of Efficacy of Antiviral and Immunotropic Therapy in Children with Hematuric Form of Chronic Glomerulonephritis and Chronic Epstein-Barr Viral Infection

Abstract

The purpose of research — to estimate the efficacy of complex antiviral and immunotropic therapy of chronic Epstein-Barr viral infection (EBVI) in children with hematuric form of chronic glomerulonephritis (HFCGN). 54 children with HFCGN and chronic EBVI aged 3–17 years were examined. Patients received preparation of recombinant interferon (IFN) α-2β (viferon®) and a medication containing flavonoids Deschampsia caespitosa L. and Calamagrostis epigeios L. (proteflazidum®), at presence of chronic EBVI activity signs patients were also administered with acyclovir. Clinical manifestations, the data of nephrological, virological, immunological examinations were estimated before treatment and in 3 months after completion of treatment. During treatment the chronic EBVI activity signs were eliminated in a half of patients. The reduction of respiratory morbidity rate, asthenic syndrome, low-grade pyrexia, systemic lymphadenopathy, hepatomegaly, intestinal syndrome, lymphocytosis and the liquidation of splenomegaly were noted. The positive dynamics of HFCGN symptoms appeared as the reduction of macrohematuria relapses, intensity of hematuria, tubular disorders. The improvement of cytokine status indexes was observed — the increase of IFN-α and IFN-γ levels and the reduction of proinflammatory cytokine levels (IL-1β and IL-6).

Keywords

• chronic glomerulonephritis
• hematuric form
• children
• Epstein-Barr viral infection
• treatment